TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31987969

Group type: EXPERIMENTAL
Intervention: Conformal photon radiation therapy (RT)
Number of subjects: 68
Study: 31988143

Group type: EXPERIMENTAL
Intervention: Late ICI-associated CAE cases (n=19, median TTO of 304 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Late ICI-associated CAE reports (n=159, median TTO 178 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Early CAE cases (n=19, median TTO of 14 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Early cases (n=437, median TTO 21 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Early CAE cases (n=19) and late CAE cases (n=19)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Early cases (n=437) and late cases (n=159)
Number of subjects: 19
Study: 31988230

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate prescribing (PIP) at admission and discharge, assessed using the newest screening tool for older persons' potentially inappropriate prescriptions.
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Adverse drug reactions (ADRs) during hospitalisation.
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Polypharmacy, defined as the number of chronic prescribed medications.
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Multimorbidity patterns identified using cluster analyses techniques.
Number of subjects: 800
Study: 31988652

Group type: EXPERIMENTAL
Intervention: Combined abdominal/pelvic trauma
Number of subjects: 16359

Group type: COMPARATOR
Intervention: Isolated pelvic fracture
Number of subjects: 16359
Study: 31988972

Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg once daily
Number of subjects: 0
Study: 31989416

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index at threshold of 85
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index of 80-89
Number of subjects: 320
Study: 31989725

Group type: EXPERIMENTAL
Intervention: Intrathecal Baclofen (ITB) therapy
Number of subjects: 1743
Study: 31989731

Group type: EXPERIMENTAL
Intervention: Chronic lung disease (CLD) cases (FEV1 z-score <-1)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group (FEV1 z-score >0)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Demographic and clinical covariates
Number of subjects: 421
Study: 31989855

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon
Number of subjects: 0
Study: 31989856

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stent (Eluvia Drug-Eluting Stent)
Number of subjects: 0
Study: 31989925

Group type: EXPERIMENTAL
Intervention: TLR5 receptor presence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pollutants and bacterial proteins activating TLR4
Number of subjects: 0
Study: 31990592

Group type: EXPERIMENTAL
Intervention: French version of the Lymphedema Functioning, Disability and Health Questionnaire (Lymph-ICF-UL)
Number of subjects: 50
Study: 31990680

Group type: EXPERIMENTAL
Intervention: Nitrogen-scavenging agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound with shear wave elastography and FibroTest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Helper-dependent adenovirus expressing Asl using a liver-specific (ApoE) promoter
Number of subjects: 0
Study: 31990685

Group type: EXPERIMENTAL
Intervention: 1.5 × 106 MICs per kg BW on day -2 (group A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.5 × 108 MICs per kg BW on day -2 (group B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.5 × 108 MICs per kg BW on day -7 (group C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MIC treatment
Number of subjects: 10
Study: 31991158

Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 353
Study: 31992108

Group type: EXPERIMENTAL
Intervention: Treatment sequences for advanced renal cell carcinoma
Number of subjects: 0
Study: 31992179

Group type: EXPERIMENTAL
Intervention: VKA
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Control (no anticoagulation)
Number of subjects: 1932
Study: 31992396

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HNS) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-OSA control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with OSA (conservative therapy or observation)
Number of subjects: 30
Study: 31992589

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 102
Study: 31992606

Group type: EXPERIMENTAL
Intervention: Step-based care model comprising psychotherapy, medication management, family support/education, peer support, and vocational/educational support.
Number of subjects: 0
Study: 31993016

Group type: EXPERIMENTAL
Intervention: Easily conducted tests during the first week post-stroke
Number of subjects: 0
Study: 31993192

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (both pools)
Number of subjects: 20
Study: 31993213

Group type: EXPERIMENTAL
Intervention: Group-based Lifestyle-integrated Functional Exercise (gLiFE) programme
Number of subjects: 6
Study: 31993275

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Gengigel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Herbal gel (Hiora SG)
Number of subjects: 30
Study: 31993453

Group type: EXPERIMENTAL
Intervention: SA4Ag
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: rMntC
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 31993561

Group type: EXPERIMENTAL
Intervention: Mayo Clinic esophageal CONDUIT tool
Number of subjects: 188
Study: 31993569

Group type: EXPERIMENTAL
Intervention: Intervention group (received counseling based on their step count)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (blinded to their step activity)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No step-tracking device group
Number of subjects: 135
Study: 31993578

Group type: EXPERIMENTAL
Intervention: Very early ART
Number of subjects: 73
Study: 31993746

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 31994009

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 120
Study: 31994250

Group type: EXPERIMENTAL
Intervention: HIV-1-infected mothers with varying CD4 counts and viral loads
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Maternal CD4 count at birth
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: High viral load
Number of subjects: 164
Study: 31994361

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 882

Group type: COMPARATOR
Intervention: Non-digoxin
Number of subjects: 882
Study: 31994788

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir
Number of subjects: 103
Study: 31995012

Group type: EXPERIMENTAL
Intervention: Benidipine + β-blocker (n=1,089)
Number of subjects: 3293

Group type: COMPARATOR
Intervention: Benidipine + thiazide (n=1,094)
Number of subjects: 3293

Group type: EXPERIMENTAL
Intervention: Benidipine + ARB (n=1,110)
Number of subjects: 3293

Group type: EXPERIMENTAL
Intervention: All three regimens (benidipine + ARB, β-blocker, thiazide)
Number of subjects: 3293
Study: 31995587

Group type: EXPERIMENTAL
Intervention: Allergic asthma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Der p 1-specific sputum IgE levels in allergic asthmatics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Total sputum IgE
Number of subjects: 56

Group type: COMPARATOR
Intervention: Total IgE levels measured in serum and induced sputum
Number of subjects: 56

Group type: COMPARATOR
Intervention: Der p 1-specific IgE levels
Number of subjects: 56
Study: 31995602

Group type: EXPERIMENTAL
Intervention: CalPen web-based tool for estimating penetrance
Number of subjects: 134
Study: 31995668

Group type: EXPERIMENTAL
Intervention: Urine gastrin-releasing peptide (GRP) levels more than 80 in the first postnatal week
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Urine gastrin-releasing peptide (GRP) levels
Number of subjects: 257
Study: 31996201

Group type: EXPERIMENTAL
Intervention: Trans-oral endoscopic thyroid surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 70
Study: 31996246

Group type: EXPERIMENTAL
Intervention: Local hope measure developed and validated among PLH
Number of subjects: 722
Study: 31996250

Group type: EXPERIMENTAL
Intervention: Integrated noncommunicable disease care management intervention leveraging WHO-PEN and HEARTS guidelines.
Number of subjects: 80000
Study: 31996898

Group type: EXPERIMENTAL
Intervention: Boys with gynecomastia
Number of subjects: 124
Study: 31996919

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 84
Study: 31997646

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31997819

Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells (hUC-MSCs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31998111

Group type: EXPERIMENTAL
Intervention: Active-tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 31998285

Group type: EXPERIMENTAL
Intervention: Neonatal antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving antibiotics)
Number of subjects: 0
Study: 31998295

Group type: EXPERIMENTAL
Intervention: Mycobacterial Growth Inhibition Assays (MGIAs)
Number of subjects: 0
Study: 31998643

Group type: EXPERIMENTAL
Intervention: High-dose ipilimumab (IPI) 10 mg/kg IV every 3 weeks for four doses starting at week 1 and high-dose interleukin-2 (IL-2) 600,000 IU/kg IV bolus every 8 h for up to 14 doses concurrently with IPI at weeks 4 and 7.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maintenance IPI (10 mg/kg IV) monotherapy administered every 12 weeks for up to 1 year after the first 12 weeks of combination therapy.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination therapy with high-dose IPI and high-dose IL-2.
Number of subjects: 9
Study: 31998651

Group type: EXPERIMENTAL
Intervention: Mobile app-based community (WalkON®) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile community-later arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile community-first arm
Number of subjects: 0
Study: 31998847

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin withdrawal
Number of subjects: 0
Study: 31998858

Group type: EXPERIMENTAL
Intervention: Corn Soy Blend Plus with oil (CSB+ w/oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn Soy Whey Blend with oil (CSWB w/oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 0
Study: 31998859

Group type: EXPERIMENTAL
Intervention: Multisectoral household agricultural and finance intervention including a human-powered water pump, microfinance loan for farm commodities, and training in sustainable farming practices and financial management.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control arm (no specific intervention details provided).
Number of subjects: 200
Study: 31998871

Group type: EXPERIMENTAL
Intervention: Multi-Mode adhesives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31999044

Group type: EXPERIMENTAL
Intervention: Alfapump
Number of subjects: 30
Study: 31999167

Group type: EXPERIMENTAL
Intervention: Reading errors scored as 'contralesional' (error in the left half of the word)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Voxelwise lesion-symptom analysis (VLSM)
Number of subjects: 110
Study: 31999499

Group type: EXPERIMENTAL
Intervention: Burn injury patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 47
Study: 31999736

Group type: EXPERIMENTAL
Intervention: Pox-protein clade AE/B alum-adjuvanted regimen (PAE/B/alum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pox-protein clade C/C MF59-adjuvanted regimen (PC/MF59)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HVTN 702 trial
Number of subjects: 0